Abstracts tagged "Biologicals"

Abstract Number: 1040 • ACR Convergence 2022
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
Uta Kiltz¹, Petros P. Sfikakis², Nicola Gullick³, ATHINA THEODORIDOU⁴, Anna Kandyli⁵, Jan Brandt-Juergens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Daniel Peterlik¹⁰, Barbara Schulz¹¹, Effie Pournara¹¹ and Piotr Jagiello¹¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ³University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁴Euromedica Geniki Kliniki, General Hospital, Thessaloniki, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Rheumatology department, University Hospital of Tours, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated a high sustained response rate in patients (pts) with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across Phase III clinical…
Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Lucia Cristina Dominguez Casas¹, Mª Paz Rodriguez Cundin², Trinidad Dierssen Sotos³, Nuria Vegas Revenga⁴, Alfonso Corrales⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco⁷, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Universidad de Cantabria, Santander, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…
Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Alba Herrero-Morant¹, Carmen Alvarez Reguera², Lara Sánchez-Bilbao², David Martínez-López², guillermo Suárez-Amorin², Raúl fernández-ramón², José Luis Martín-Varillas³, Cristina Mata⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Cantabria, Spain, ⁴Hospital Laredo, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…
Abstract Number: 1994 • ACR Convergence 2022
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Lotte van Ouwerkerk¹, Sytske Anne Bergstra², Tjardo Maarseveen¹, Rachel Knevel¹, Tom Huizinga¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…
Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Alen Zabotti¹, Sarah Ohrndorf², William Tillett³, Marlies Neuhold⁴, Michel van Speybroeck⁵, Elke Theander⁶, Christine Contré⁷, Mohamed Sharaf⁸, May Shawi⁹, Michelle Perate¹⁰, Alexa Kollmeier¹¹ and Pascal Richette¹², ¹Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Janssen Cilag, Lund, Sweden, ⁷Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁸Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Amy Mudano¹, Gary Cutter², Ted Mikuls³, Geoffrey Thiele⁴, Mark Law⁴, Bart Hamilton⁴, Michael Zikry⁵, Kelly Y. Chun⁶, Monique Bastidas⁷, Michael George⁸, Lisa Williams⁹, Kevin Winthrop¹⁰, Mark Busch¹¹, Stanley Cohen¹², Roman Czubatyj¹³, Rajesh Kataria¹⁴, Reshma Khan¹⁵, Soha Mousa¹⁶, Jose Pando¹⁷, Elizabeth Perkins¹⁸, Shanmugapriya Reddy¹⁹, Delfin Santos²⁰, Joy Schechtman²¹, Frank Scott²², Sucharitha Shanmugam²³, Atul Singhal²⁴, John Tesser²⁵, John Tower²⁶, Swamy Venuturupalli²⁷, Sean Joseph Wollaston²⁸, Conrad Ziembinski²⁹ and Jeffrey Curtis³⁰, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵LabCorp, Burlington, NC, ⁶Labcorp, Calabasas, CA, ⁷LabCorp, Northridge, CA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Illumination Heath, Hoover, AL, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹Family Arthritis Center-Jupiter, Jupiter, FL, ¹²Metroplex Clinical Research Center, Pittsburgh, PA, ¹³Arthritis Physicians LLC, Rochester Hills, MI, ¹⁴Southern Ohio, Wheelersburg, OH, ¹⁵Palm Beach Rheumatology and Wellness, Jupiter, FL, ¹⁶Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, ¹⁷Rheumatology Consultants of DE, Lewes, DE, ¹⁸Rheumatology Care Center, Hoover, AL, ¹⁹Southwest Florida Rheumatology, Riverview, FL, ²⁰Rochester Rheumatology, Rochester Hills, MI, ²¹SunValley Arthritis Center, Peoria, AZ, ²²Arthritis Medical Center, Arroyo Grande, CA, ²³Rheumatology and Arthritis Care Center, Exton, PA, ²⁴Southwest Rheumatology Research, Mesquite, TX, ²⁵Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²⁶Arthritis Physicians LLC, Rochester, MI, ²⁷Cedars-Sinai Medical Center, Los Angeles, CA, ²⁸Rheumatology Associates, North Hollywood, CA, ²⁹CZ Rheumatology, Coral Springs, FL, ³⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Bryant England¹, Michael George², Yangyuna Yang¹, Punyasha Roul³, Jorge Rojas⁴, Brian Sauer⁵, Grant Cannon⁶, Joshua Baker⁷, Jeffrey Curtis⁸ and Ted Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA, Salt Lake city, ⁷University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁸Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…
Abstract Number: 0350 • ACR Convergence 2022
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Vicente Aldasoro¹, María Laiño¹, Monica Enguita¹, Santos Castañeda², Javier Loricera³, Carmen Lasa-Teja⁴, Clara Moriano⁵, Vanesa Calvo Río⁶, Ivette Casafont-Solé⁷, Judit Font Urgelles⁷, Patricia Quiroga-Colina⁸, Samuel Hernandez⁹, Sergi Heredia¹⁰, A. Garcia-Aparicio¹¹, Joaquin Maria Belzunegui Otano¹², Aaron Fariña¹³, Francisco Javier Navarro Blasco¹⁴, Patricia Fanlo Mateo¹, Adela Gallego¹⁵, Juan M Blanco Madrigal¹⁶, María Ángeles Matías¹⁷, Cilia Peralta¹⁸, Jordi Camins-Fàbregas¹⁹, Marcos Paulino²⁰, Ana Urruticoechea²¹, Piter Jose Cossio Jimenez²², Miguel Medina Malone²³, Eva Perez Pampin²⁴, Rafaela Ortega-Castro²⁵, Blanca varas de Dios²⁶, Jose Ramon Lamua Riazuelo²⁷ and Emilio Jose Giner²⁸, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Complejo Asistencial Universitario de León, León, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁹Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁰Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain, ¹¹Hospital Universitario de Toledo, Toledo, Spain, ¹²Hospital Universitario de Donostia, Donostia-San Sebasti, Spain, ¹³Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Hospital General Universitario de Elche, Elche, Spain, ¹⁵Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁶Basurto University Hospital, Bilbao, Spain, ¹⁷Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Hospital General de Granollers, Granollers, Spain, ²⁰Hospital General Universiario de Ciudad Real, Ciudad Real, Spain, ²¹Hospital Can Misses, Ibiza, Spain, ²²Hospital Reina Sofia, Tudela, Spain, ²³Hospital Calahorra, Calahorra, Spain, ²⁴Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ²⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²⁶Santa Cristina Hospital, Madrid, Spain, ²⁷Hospital Universitario del Henares, Madrid, Spain, ²⁸Hospital Royo Villanova, Zaragoza, Spain
Background/Purpose: To describe demographic characteristics, efficacy and safety of BLM since its approval in SLE patients in a real-world setting. Methods: Descriptive, retrospective, multicenter study…
Abstract Number: 0431 • ACR Convergence 2022
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Ana Lúcia Martins Fernandes¹, Ana Pinto², Kalveer flora³, dilpreet matharu³, anthony isaacs³ and Pedro Machado⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Local Health Unit of Guarda, Barcelos, Portugal, ³Northwick Park Hospital, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Biotherapeutics have revolutionized the treatment of axial spondyloarthritis (axSpA). The emergence of biosimilars allowed substantial savings and a wider access to treatment, and international…
Abstract Number: 0779 • ACR Convergence 2022
Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab
Cassandra Calabrese¹, Elizabeth Kirchner², alexandra villa forte², Rula Hajj-Ali³, Carol Langford⁴, james Fernandez², Alise Carlson², Brandon Moss², Vickie Sayles⁴, Andrea Pallotta², Alice kim² and Leonard Calabrese⁴, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Hunting Valley, OH, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: Patients receiving B cell depleting therapies (BCDT) for immune mediated inflammatory diseases (IMIDs) have high risk of poor COVID-19 outcomes and strategies for COVID-19…
Abstract Number: 0888 • ACR Convergence 2022
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Nathalie Carrier¹, Sophie Roux², Hugues Allard-Chamard² and Gilles Boire³, ¹Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ²Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ³Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
Abstract Number: 1043 • ACR Convergence 2022
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
Jan Brandt-Juergens¹, Martin Rudwaleit², Frank Behrens³, Christopher Ritchlin⁴, Daniel Peterlik⁵, Erhard Quebe-Fehling⁶, Renato Calheiros⁷ and Atul Deodhar⁸, ¹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ²University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁴Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corp., Hoboken, NJ, ⁸Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Uveitis is one of the most frequently reported extra-musculoskeletal manifestations of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1,2 The prevalence of anterior uveitis is…
Abstract Number: 1407 • ACR Convergence 2022
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
Reinder Raadsen¹, Laurette van Boheemen¹ and Michael Nurmohamed², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular diseases (CVD). This is partly due to the systemic inflammation characteristic to…
Abstract Number: 1564 • ACR Convergence 2022
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
Nuria Barroso-García¹, Belén Atienza-Mateo², Ivan Ferraz Amaro³, Diana Prieto-Peña², Ana De Vicente-Delmás⁴, Ricardo Blanco⁵ and Miguel Ángel González-Gay⁶, ¹Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital General Santa María del Puerto, Cádiz, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: To evaluate the efficacy of anti-TNF or anti-IL6 treatment in severe and refractory ocular involvement in patients with refractory cystoid macular edema (CME) due…
Abstract Number: 2001 • ACR Convergence 2022
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Tanya Shivacheva, Medical University prof.dr. P. Stoyanov, Varna, Bulgaria, Varna, Bulgaria
Background/Purpose: Sustained targeted therapeutic outcome with biological therapy in real clinical conditions is not yet achievable in a large proportion of rheumatoid arthritis (RA) patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].